Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-centre, single-arm, open-label trial
<strong>Background</strong> Alström syndrome (ALMS) is a very rare autosomal recessive monogenic disorder caused by a mutation in the ALMS1 gene and characterised by childhood onset obesity, dyslipidaemia, advanced non-alcoholic fatty liver disease, diabetes and extreme insulin resistanc...
Main Authors: | Baig, S, Veeranna, V, Bolton, S, Edwards, N, Tomlinson, J, Manolopoulos, K, Moran, J, Steeds, R, Geberhiwot, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2018
|
Similar Items
-
Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial
by: Shanat Baig, et al.
Published: (2018-11-01) -
Alström syndrome: a paradigm for diffuse fibrosis and clinical progression
by: Edwards Nicola C, et al.
Published: (2013-01-01) -
Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
by: Shanat Baig, et al.
Published: (2020-06-01) -
Phenoage and longitudinal changes on transthoracic echocardiography in Alström syndrome: a disease of accelerated ageing?
by: Patel, L, et al.
Published: (2023) -
Alström syndrome: the journey to diagnosis
by: Akshat Sinha, et al.
Published: (2025-01-01)